Source:

Nursing2015

October 2007, Volume 37 Number 10 , p 30 - 30 [FREE]

Authors

Abstract

 

Administered via transdermal system, rivastigmine (Exelon Patch) has received FDA approval to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. The drug, an acetylcholinesterase inhibitor, was previously approved in oral capsule and solution forms.

 

Although not a cure, rivastigmine may help slow the progression of dementia by inhibiting the destruction of acetylcholine, a neurotransmitter necessary for learning and memory.

Administered via transdermal system, rivastigmine (Exelon Patch) has received FDA approval to treat mild to moderate dementia associated with Alzheimer's disease and Parkinson's disease. The drug, an acetylcholinesterase inhibitor, was previously approved in oral capsule and solution forms.

Although not a cure, rivastigmine may help slow the progression of dementia by inhibiting the destruction of acetylcholine, a neurotransmitter necessary for learning and memory.